Hematologic toxicity and double autografting of stem cells after myeloablative activities of yttrium-90-ibritumomab tiuxetan.
Vanazzi
Anna
A
Cremonesi
Marta
M
Paganelli
Giovanni
G
Martinelli
Giovanni
G
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000191:economics; D033581:Stem Cell Transplantation / Q000191:economics / Q000379:methods*; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000191:economics
D000911:Antibodies, Monoclonal; C422802:ibritumomab tiuxetan